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GENE EXPRESSION SIGNATURE AS A DIAGNOSTIC TEST FOR THORACIC AORTIC ANEURYSMS: A 
VALIDATION STUDY. Adam X. Sang, Catalin C. Barbacioru, Gregory A. Kuzmik, Laura Ondere, 
Maryann Tranquilli, Jon K. Sherlock, John A. Elefteriades. Department of Surgery, Yale University 
School of Medicine, New Haven, CT. 
 
Thoracic aortic aneurysms (TAAs) are clinically-silent diseases that predispose 
individuals to life-threatening aortic dissection or rupture. If detected early, TAAs can be safely 
treated with elective surgery. Therefore, there is a great clinical need in screening for TAAs. 
However, no reliable screening programs exist, and radiographic imaging is too costly and 
harmful for screening entire at-risk populations.  We hypothesize that a novel diagnostic blood 
test based on the gene-expression profiles of a previously-identified panel of 41 genes (a RNA 
signature) is greater than 70% sensitive in detecting TAAs. Using RNA extracted from peripheral 
blood cells of 40 individuals (24 TAA patients and 16 spousal controls), we performed real-time 
PCR using customized TaqMan Array Cards to analyze the relative expression levels of this panel 
of genes. A 10-fold cross-validation study based on these expression levels was used to predict 
whether each sample belonged to a TAA patient or a spousal control. When compared with 
each sample’s true clinical status, this RNA signature-based prediction model was 83% accurate, 
with a sensitivity of 88% and a specificity of 75%. Furthermore, the expression levels of the 
individual genes were largely consistent with their expression levels from a previous study of 
this RNA signature (r2 = 0.75 for TAA patient samples, and r2 = 0.73 for spousal control samples), 
supporting the reproducibility of this test. Altogether, these findings demonstrate that gene-
expression profiling is an accurate, sensitive, and reliable method for detecting TAAs.  If utilized 
as a clinical screening test, this RNA signature has the potential to detect silent TAAs, leading to 
earlier diagnosis and reduced mortality of this dangerous condition. 
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Introduction 
 
Section 1: Thoracic aortic aneurysm is an asymptomatic disease 
Thoracic aortic aneurysm (TAA) is a chronic disease that affects the main artery of the 
body, the aorta. The aorta is a large elastic artery that originates from the heart, ascends and 
then descends in the chest cavity (thoracic aorta), traverses the diaphragm, and continues its 
downward course as the abdominal aorta. Important arteries that supply the head, arms, spine, 
gastrointestinal tract, and kidneys all branch from the aorta. The average size of a “normal” 
human ascending aorta is approximately 3.0 cm for men and 2.7 cm for women, based on older 
studies (1, 2). 
An aneurysm is an enlargement, or dilatation, of a blood vessel—the extent of dilatation 
for an aneurysm is usually defined as greater than 50% of the “normal” diameter of the blood 
vessel (3). For the ascending aorta, physicians have also adopted 4.0 cm as a hard cutoff for the 
upper limit of a normal (4). This thesis work focuses on ascending TAAs and arch TAAs, which 
make up 60% of all TAAs (5). 
A great physician in the late nineteenth century once remarked that “there is no 
condition more conducive to clinical humility than aneurysm of the aorta” (6). This physician 
was Sir William Osler, one of the fathers of modern medicine, the first Professor of Medicine at 
Johns Hopkins Hospital, and founder of our current medical residency structure.  His observation 
highlights one of the challenges of the management of aortic aneurysms that still persists today, 
namely, the initial diagnosis and detection of a disease that is a clinically-silent killer. 
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TAAs are asymptomatic in over 90% of cases (4, 6). They rarely produce pain. In those 
patients who do complain of pain from stretching of the aortic tissue or discomfort from 
impingement, the pattern and characteristic of the symptoms are non-specific and varied. We 
have published case reports in which non-specific pain portended an impending acute disaster 
for patients with TAAs, discovered only with surgical exploration (7-9).  
Additional symptoms can arise when the aneurysm progresses to very large dimensions.  
If the aneurysm involves the aortic root, the aortic valves can become incompetent in 
preventing backflow of blood into the heart. This aortic regurgitation can produce a diastolic 
heart murmur on auscultation. With severe aortic regurgitation, the patient can become short 
of breath and develop heart failure. Occasionally, the enlarged aorta can exert a mass effect and 
compress on the trachea or the esophagus. 
 
Section 2: Thoracic aortic aneurysms are likely more prevalent than we 
recognize 
How common are thoracic aortic aneurysms? 
Given their asymptomatic nature, it is difficult to truly estimate the prevalence of this 
disease in the general population, as many individuals can harbor TAAs without ever knowing 
about it. Recent studies that examined the prevalence of asymptomatic TAAs using population-
wide computed tomography (CT) screening report a prevalence range of 0.16% to 0.34%  (10, 
11). However, these studies used a fixed cutoff diameter of 5 cm to define an aneurysm, thereby 
omitting potential aneurysms in the 4 to 5 cm range.  
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It is also interesting to consider the rate at which new cases of TAAs are being 
discovered and diagnosed. The annual incidence of TAAs is approximately 6 to 10 per 100,000 
patient-years (12, 13). Men and women have similar incidences of TAA, although women are 
considerably older at the time of detection (13). This is in contrast to abdominal aortic 
aneurysms, which predominately affect men. 
A Swedish national healthcare registry study reported that from 1987 to 2002, the 
incidence of thoracic aortic diseases (includes both TAAs and thoracic aortic dissections, which 
are described below) rose by 52% to 16.3 per 100,000 patient-years in men, and by 28% to 9.1 
per 100,000 patient-years in women (14). While the increasing incidence of TAAs, which 
continues to modern times, is undoubtedly influenced by the aging population and increasingly 
frequent use of radiographic imaging, there is some evidence suggesting a bona fide increase in 
the true incidence of this disease (15, 16).  
Altogether, aortic aneurysms of both the thorax and abdomen combine to form the 19th 
leading cause of death in the United States today. In addition, aortic aneurysms are the 15th 
leading cause of death in individuals over the age of 65 (17). 
 
Section 3: The underlying etiology of thoracic aortic aneurysms is 
diverse.   
TAAs can either be sporadic or genetically inherited. The majority of TAAs, to our 
current knowledge, are sporadic—these aneurysms are thought to be the result of a chronic 
degeneration of the aortic wall. Hypertension, advanced age, and smoking can accelerate this 
process: high blood pressure increases the wall tension of the aorta, while advanced age and 
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smoking cause global tissue weakening (4). The common histological finding associated with the 
degenerative changes of the aortic wall is termed cystic medial necrosis. This process involves a 
gradual loss of both the cellular (smooth muscle cells) and acellular (elastic fibers) elements of 
the middle layer of the aortic wall, the tunica media (5). This loss is in part caused by increased 
amounts of proteolytic enzymes, such as matrix metalloproteinases (18, 19).   In addition, there 
are increased numbers of inflammatory cells, specifically T lymphocytes and macrophages, in 
the tunica media of aneurysmal aortas (20). 
Other TAAs have a genetically-inherited component. The most dramatic manifestation 
of such TAAs can be found in connective tissue disorders. Connective tissue disorders are 
syndromes that affect multiple tissue and organ types, and virtually all patients with these 
syndromes develop dilatation of the aorta. The most common connective tissue disorder is 
Marfan syndrome, an autosomal dominant disease in which a mutation in the fibrillin (FBN1) 
gene reduces its ability to sequester transforming growth factor beta (TGF-β). The excessive 
TGF-β results in the weakening of several components of the extracellular matrix, including 
elastin.  Other genetic syndromes associated with TAAs include Ehlers-Danlos syndrome (a 
defect in the synthesis of collagen) and the recently discovered Loeys-Dietz syndrome (a 
mutation in TGF-β). 
TAAs associated with connective tissue disorders, however, only represent the tip of the 
iceberg for genetically-inherited forms of TAA. An isolated TAA, passed from generation to 
generation, in the absence of other medical conditions or syndromes, is increasingly recognized 
as a clinical entity. This “familial TAA” is likely a common manifestation of an unknown number 
of heterogeneous genetic mutations. Approximately 21% of patients diagnosed with TAAs have 
at least one family member who also has a known aneurysm (21).  We can surmise that many 
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additional TAA patients have family members harboring unknown aneurysms. Of these familial 
forms of TAA, the majority (77%) appears to be inherited in an autosomal dominant manner, 
based on pedigree studies (21, 22). The penetrance and expressivity of familial TAAs are varied. 
Currently, individual mutations in five different genes (TGFβR1, TFGβR2, FBN1, ACTA2, and 
MYH11) have been identified as contributing to aneurysm formation (3, 23). Searching for 
additional mutations is an active area of research. 
Several other lines of evidence support the concept that TAA is a genetic disease. First, 
in patients with known TAAs, there is an increased prevalence of other types of aneurysms, such 
as abdominal aortic aneurysms (24, 25) and intracranial aneurysms (26, 27), beyond that of the 
general population. This phenomenon suggests that rather than multiple, independent 
aneurysms forming sporadically, there is a common underlying molecular pathway, perhaps a 
single gene defect, that is responsible for the pathogenesis of different aneurysm types. Second, 
patients with bicuspid aortic valves (BAV), a congenital heart defect in which the aortic valve has 
two leaflets instead of the usual three, are abnormally susceptible to aortic dilatation (28). BAV 
is a genetic condition that appears to be inherited in an autosomal dominant manner. TAA 
patients with BAVs also have faster rates of aortic dilatation than TAA patients with normal 
tricuspid aortic valves (29). Perhaps BAV and TAA are variable manifestations of the same 
heritable disease (23). 
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Section 4: All forms of thoracic aortic aneurysms can progress to lethal 
outcomes 
Despite their diverse etiologies, all TAAs are prone to two lethal acute events: aortic 
dissection and aortic rupture. Whereas TAA is a clinically-silent disease, aortic dissection and 
aortic rupture are dramatic and life-threatening events, and must be prevented.  
Aortic dissection is a catastrophic event in which the layers of the aortic wall split apart. 
A tear in the tunica intima (the innermost layer of the aorta) allows blood to enter and shear 
apart the tunica media. Blood can continue to track along this false lumen (the space in between 
the layers), propagating the dissection. Eventually, important branches of the aorta, or the aorta 
itself, can be occluded if the dissection flap covers the true lumen of the aorta. 
Aortic dissection is classically accompanied by a tearing or stabbing pain, so sudden and 
excruciating that most patients remember the exact moment it occurred (30). Additional 
symptoms are dictated by the anatomical site of dissection. Type A dissections are more 
surgically urgent because they can occlude the coronary arteries, the first branches of the 
ascending aorta, which supply blood to the heart itself, or tamponade the heart sac. These 
dissections can present with angina, or sudden death, depending on the degree of occlusion. 
Dissections in the arch of the aorta can produce the classic “pulse deficit,” in which the blood 
pressure of the left arm is markedly different from that of the right arm. Type B dissections and 
dissections of the abdominal aorta can occlude branches of the spinal arteries, splanchnic 
arteries, or renal arteries, producing paraplegia/paresthesia, abdominal pain, and renal failure, 
respectively. In reality, however, aortic dissection has such a diversity of clinical manifestations 
that it is commonly misdiagnosed as myocardial infarction, pericarditis, heart failure, pulmonary 
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embolism, or pneumothorax (31). Misdiagnoses or delayed diagnosis further exacerbates the 
prognosis of the disease. 
 An aortic rupture is a related catastrophe in which there is a complete tear or 
transection through all three layers of the aorta, resulting in massive internal hemorrhage. 
Symptoms include hypovolemic shock, multi-organ failure, and more frequently, sudden death. 
Aortic dissection and aortic rupture occur with approximately the same incidence of 3.5 
to 5 per 100,000 patient-years (32, 33). However, because many cases of sudden death are 
attributed almost reflexively to myocardial infarction, the true incidence of dissection or rupture 
may be higher (31). Patients with Marfan syndrome have an even higher risk of dissection, at 40% 
per individual (28). 
The exact moment when an aorta dissects or ruptures is a function of several variables. 
A very important predictor is the size, or diameter, or the aorta. An aneurysmal ascending aorta 
grows at approximately 0.10 cm per year, whereas descending TAAs grow by 0.29 cm per year 
(34, 35). The annual risk of an acute event (dissection or rupture) is approximately 2% for aortas 
measuring 4.0 to 4.9 cm, and 3% for aortas measuring 5.0 to 5.9 cm (36). However, for 
ascending aortas larger than 6.0 cm, the risk of acute events increases sharply: the annual 
rupture or dissection rate is 6.9%, and the annual mortality is 11.8% from all causes (35, 36).  
Activities that acutely increase systolic blood pressure are also risk factors for 
precipitating aortic dissection or rupture. Weight lifting and other physical exertions have been 
repeatedly linked to dissections and ruptures of pre-existing aneurysms (37, 38). Even emotional 
stress can precipitate aortic dissections, accounting for up to 40% of acute dissections in one 
series (30). External trauma or medical instrumentation to the aorta can also trigger the 
dissection event. 
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Regardless of cause, once a TAA dissects or ruptures, the patient’s prognosis worsens 
rapidly. For patients with acute dissections who make it to the hospital, the overall in-hospital 
mortality is 27.4% (39). The in-hospital mortality for Type A dissection is 35%, and 12% for Type 
B dissection (39, 40). 
A ruptured TAA is a more lethal event. Based on an older (1995) retrospective study 
from Sweden, only 41% of patients with TAA rupture reach the hospital alive, but the overall 
mortality  from rupture is 97%, making the disease almost uniformly fatal (32). The 30-day 
mortality for all TAA ruptures is 71%. Even amongst those who undergo surgical treatment for 
rupture, the 30-day mortality is high, at 35% (14). Our ability to rescue patients with ruptured 
TAAs has improved over time—however, aortic rupture is still the leading cause of aneurysm-
related death in TAA patients, accounting for 60% of the mortality (33). Interestingly, 79% of 
TAA ruptures occur in women (13).  
 
Section 5: Diagnosis and screening for thoracic aortic aneurysms remain 
challenging 
Given that untreated TAAs can progress to acute lethal events such as aortic dissection 
or aortic rupture, screening for asymptomatic TAAs before these events occur is of great clinical 
importance.  
However, there are no standard screening programs for TAAs. Consequently, TAAs are 
commonly detected incidentally. In many cases, a patient might have his or her TAA detected 
while undergoing an echocardiogram (ECHO, or cardiac ultrasound) study or a CT scan for a 
completely unrelated reason.  In other cases, a cluster of non-specific complaints, such as 
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fatigue, exercise intolerance, shortness of breath, or chest pain, might prompt the initiation of a 
long work-up which ultimately reveals an aortic, not cardiac, cause of the complaints. It is 
possible that the challenges of diagnosing TAAs, and the adverse outcomes of a missed 
diagnosis, are what Sir William Osler alluded to in his remarks about clinical humility. 
Our advanced imaging technologies have allowed us great insight into the anatomy of 
the disease and provide a robust method for visualizing the aorta. However, these techniques 
have shortcomings as screening methods, including high cost, inconvenience, invasiveness, or 
harmfulness. 
The issue of which imaging modality should be used to initially screen for aortic 
aneurysms is an ongoing area of debate. Chest X-rays are commonly used to screen for cardiac 
or pulmonary diseases due to their cost-effectiveness and low radiation exposure. The widening 
of the mediastinum, the central compartment of the thorax that contains the heart and aorta, is 
a classic radiographic sign of a TAA, but chest X-rays have an overall sensitivity of less than 70% 
for TAAs (41). Echocardiography (ECHO) is a convenient and safe method for examining 
aneurysms. However, ECHOs can only detect aneurysms of the aortic root or the first part of the 
ascending aorta due to its limited penetrance.  In addition, ECHO is very operator dependent, 
and the accuracy of the measurements is affected by artifacts/interference, body habitus, and 
the presence of lung disease. 
More sensitive imaging modalities have their drawbacks as well. Ultrasound applied 
from within the esophagus (trans-esophageal echocardiography, TEE) offers better resolution 
because of the proximity of the esophagus to the aorta, but it is an invasive method that 
requires sedation. CT scanning is widely available, easy and quick to operate, and provides 
excellent resolution. It is generally preferred over echocardiography for comprehensively 
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visualizing thoracic aortic anatomy and disease (3). As a routine screening method, however, CTs 
are impractical because of high cost, high radiation exposure, and toxicity from the contrast dye 
needed to visualize vascular structures. Magnetic resonance imaging (MRI), on the other hand, 
does not require exposure to radiation or harmful contrast agents, and provides excellent 
imaging of cardiovascular tissue. Drawbacks for MRIs include longer imaging times, 
incompatibility with metallic implants (e.g. pacemakers), need for sedation, very high operating 
costs, and lower spatial resolution than CTs. 
Finally, because ascending TAAs are at much higher risk of acute events once the 
diameter approaches 6.0 cm, and because TAAs grow at a slow rate of 0.1 cm per year on 
average, obtaining precise measurements is paramount for prognosis and clinical decision-
making (34, 36). And yet, there are many sources of error that can contribute to an imprecise 
measurement. In addition to the innate spatial resolution of the imaging modality, the 
measurement of the diameter is affected by whether the aorta is in systole or diastole, whether 
the aortic wall is included in the measurement, and whether a diameter measurement that is 
perfectly perpendicular to the direction of blood flow can be obtained from orthogonal views (3). 
 
Section 6: Once diagnosed, thoracic aortic aneurysms can be safely 
treated with surgery 
There is great clinical utility in screening for asymptomatic TAAs because there are 
effective treatments available. It is critically important to detect the aneurysm before it reaches 
dangerous diameters, as surgical treatment is safest and most effective on an elective basis, that 
is, before acute aortic rupture or dissection occurs. 
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Based on clinical studies which demonstrated that the risk of aortic rupture or dissection 
sharply increases as the ascending aorta approaches 6.0 cm, or as the descending aorta 
approaches 7.0 cm, the current guidelines recommend replacing the ascending aorta before it 
reaches 5.5 cm, and the descending aorta before it reaches 6.5 cm (3, 35, 42). The exact timing 
of surgical intervention, however, is a complex, multifactorial clinical decision that must take 
into account other factors, such as patient and family readiness (which includes their possible 
preference of living with a 2% dissection or rupture rate annually, versus facing a one-time risk 
of surgery), and the presence of other comorbidities. In addition, aneurysms that are 
symptomatic, or demonstrate a rapid rate of enlargement over recent years (> 0.5 cm/year), 
warrant repairs at smaller diameters (3, 9). TAAs associated with BAV or Marfan syndrome also 
warrant earlier repair, possibly as early as the 4.0 to 5.0 cm range (3, 15).  
There are two main treatment options for TAAs on an elective basis. The first option is 
open surgery, in which the dilated, aneurysmal portion of the native aorta is excised, and a 
synthetic Dacron graft, measured for appropriate width and length, is sutured in its place. 
Ascending TAAs and TAAs of the aortic arch are approached through a mid-sternotomy (a 
midline incision through the sternum), whereas descending TAAs are approached through a 
lateral thoracotomy (an incision through the left rib cage). Both approaches require the use of a 
cardiopulmonary bypass machine. 
The second, newer, option is an endovascular approach, in which a metallic stent with 
an intimal fabric graft is inserted through a small incision in the femoral artery at the groin, and 
deployed under X-ray guidance into the aneurysmal portion of the aorta. The stent is deployed 
against the inner surface of the aorta. Currently, endovascular approaches alone cannot address 
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ascending and arch disease without associated open surgical procedures; descending aneurysms 
and abdominal aneurysms benefit the most from endovascular approaches. 
The immediate and long-term outcomes of both procedures are favorable when 
performed in elective settings. For surgical treatment, the 5-year survival after elective 
treatment is between 73 and 85%, and approaches the survival curve of a healthy, age-matched 
population (36, 43). By contrast, the 5-year survival after emergency surgical intervention is less 
favorable, at 37% (36). At experienced institutions, the perioperative mortality and complication 
rates, including bleeding, stroke, and paraplegia, are around 3% (43). Several trials have been 
initiated to examine whether endovascular approaches are as durable as open graft repairs (4). 
Early reports show favorable outcomes of endovascular repair of TAAs and dissections, with 30-
day mortalities of 0% in an elective setting and 2.9% in an emergent setting (44). However, long-
term outcomes are uncertain. Currently, ascending TAAs are still treated surgically. 
 
Section 7: There is potential in using biomarkers to screen for aneurysm 
disease 
Although many cases of aortic aneurysms are detected by CT or MRI, these modalities 
are not safe or cost-effective as screening methods for the general population. Relying on 
radiographic images alone for the diagnosis and management of TAAs also has two other 
shortcomings. First, a patient who has an aortic diameter that is smaller than the threshold for 
an aneurysm at the time of scanning might be declared to be aneurysm-free, but may develop 
an aneurysm later in life. The radiographic image is just one snapshot in time. Second, although 
aortic size can predict when aortic dissection or rupture may occur, as described above, the 
classification is not perfect, as some individuals dissect well below 5.5 cm (45). 
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Therefore, there is a need for better screening methods for TAA. Laboratory blood tests, 
thus far, have played a very limited role for aneurysm diseases. However, there are several 
potential benefits to using a blood test to screen for aneurysms. A blood test is cheap, safe, non-
invasive, and widely available. They can be performed multiple times to monitor an aneurysm 
over time, without accumulating radiation or contrast toxicity. In addition, they may reveal 
pathologic details about the aneurysm that an image alone cannot. 
Blood tests are designed to detect the biomarkers of a disease. A biomarker, in the 
general sense, is a molecular indicator of a biological process or state. In clinical application, 
biomarkers are reflective of the pathogenic activity of that disease. A biomarker must be able to 
be measured objectively and quantitatively. The quantity of the biomarker can correlate with 
the type, risk, or severity of disease. Therefore, the appropriate biomarkers may tell us not only 
whether an aneurysm exists, but how dangerous it is or how close it is to dissection or rupture. 
Biomarkers may even be able to predict aneurysm formation well before dilatation can be 
detected on CT. 
The use of blood-based biomarkers for aneurysm disease is still in its infancy. The panel 
of available or investigational biomarkers is reviewed in Trimarchi et al. (46). These potential 
biomarkers include D-dimers, the product of cross-linked fibrin which appear to be elevated 
after aortic dissections; matrix metalloproteinases, which not only participate in the 
pathogenesis of aneurysms, but appears to be further elevated during aortic rupture and 
dissections (18); smooth muscle myosin, which is sensitive and specific for aortic dissections (47); 
and C-reactive protein, whose level actually correlates with the size of the abdominal aortic 
aneurysm (48). 
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While many of these biomarkers of aortic aneurysms have shown promise, they have 
not led to any clinically utilized testing programs. In many cases, the biomarker has only been 
shown to be of value after the acute aortic event. In addition, several biomarkers were tested 
on small patient cohorts, not tested within a clinical setting at all, or examined exclusively for 
abdominal aortic aneurysms. Finally, many of these biomarkers, including D-dimer and CRP, are 
very non-specific for aneurysm disease. 
In 2007, Wang et al. published a study in which a comprehensive gene expression 
analysis of peripheral blood cells (PBCs) was conducted on blood samples from TAA patients, 
with spouses as controls.  Using the Applied Biosystems Human Genome Survey Microarray, 
which represents 29,098 individual human genes, a panel of 41 classifier genes that were the 
most significantly over- or under-expressed in TAA samples versus control samples was 
identified (49). Genes in this classifier set included those integral to interleukin signaling, T-cell 
activation, and apoptosis.  These biological pathways have all been shown to be associated with 
aneurysm formation (50-52). 
When tested on a mixed cohort of TAA patients and spousal controls, the RNA signature 
succeeded in distinguishing the two groups with an overall accuracy of 78% (sensitivity = 72%, 
specificity = 90%).  The validity of this 41-gene RNA signature was subsequently reassessed 
through real-time polymerase chain reaction (qPCR) using the TaqMan Gene Expression assay, 
which provides a more precise quantification of expression levels than microarray. This initial 
validation tested a small cohort of 30 samples (mixed pool of patients and controls) on a 384-
well format, using the 7900HT Fast Real-Time PCR System (Applied Biosystems). This real-time 
PCR study demonstrated that the RNA signature was 80% accurate (sensitivity = 71%, specificity 
= 100%). 
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These results show promise for a gene-expression-based biomarker that can be used to 
screen for TAAs. Such a biomarker can be easily instituted as a blood test, and has proven to be 
both sensitive and specific for TAAs. While none of the 41 classifier genes alone are specific for 
aneurysm disease, the panel simultaneously examines the relative expression levels of all 41 
genes, and predicts a diagnosis based on a multiple regression model. Investigation and 
revalidation of this new entry biomarker for TAA disease is the objective of this current study. 
16 
 
 
Statement of Purpose 
 
There is an important role for screening tests for thoracic aortic aneurysms. TAAs are 
asymptomatic, lift-threatening, but treatable once diagnosed. Many patients can benefit from 
early detection. However, there are no standard screening tests for TAAs at present. 
Radiographic imaging, such as CT scans and angiograms, are the gold standards for visualizing 
and confirming TAAs. However, these modalities are not ideal as screening tests because of high 
costs, low accessibility, and harmfulness.   
The purpose of this current study is to reevaluate the sensitivity and specificity of a 
novel screening test for TAAs. This screening test is based on relative expression levels of a 
panel of genes (a “RNA signature”). A previously published study demonstrated that this 41-
gene RNA signature was 72% sensitive and 90% specific in distinguishing TAA patients from 
spousal controls (49). Further testing of this signature using TaqMan real-time PCR showed that 
the assay was 71% sensitive and 100% specific. 
These preliminary results suggest a promising role for this RNA signature to serve as a 
screening test for TAA for perhaps the general population. In its maturity, this screening test 
would be a simple blood test that would determine a single probability of the individual having a 
TAA. A high probability would then warrant subsequent confirmatory studies, such as CT scan. 
 
Specific Hypothesis 
For screening tests, a high level of sensitivity is important. Based on these previous 
findings, we hypothesize that a revalidation study of these 41 classifier genes, using TaqMan 
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real-time PCR, will demonstrate a sensitivity greater than 70%, and a specificity greater than 
60%, in distinguishing TAA patients from healthy, spousal controls. We will be comparing the 
predicted diagnosis of the blood test (“TAA” or “control”) against the gold standard (the 
radiographic documentation of TAA). 
 
Specific Aims 
The specific aims of this study are: 
1) To reproduce the findings from Wang et al., 2007, by revalidating the sensitivity and 
specificity of this RNA signature test in detecting TAAs on a new, independent cohort of 
patients; 
2) To demonstrate the efficacy of a new TaqMan Array Cards (TAC) format for real-time 
PCR analysis of these classifier genes. The previous study by Wang et al. utilized a 384-
well format. 
This study will confirm whether the RNA signature is able to distinguish TAA patients 
from spousal controls within a mixed pool. Because this mixed pool comprises of TAA patients 
from Dr. John A. Elefteriades’ clinical practice at Yale-New Haven Hospital, and their consenting 
spouses, the prevalence of TAA within this cohort is drastically higher than that of the general 
population. Therefore, this study will not assess the positive and negative predictive values of 
the RNA signature test, which are based on the true prevalence of a disease in the population. 
The long-term goal of this and subsequent studies is to develop a clinical blood test for 
TAAs. With this goal in mind, consideration was given to the logistics of engineering and 
marketing a laboratory diagnostic test. One such consideration is to streamline the workflow, 
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from the time of phlebotomy to the acquisition of test results. Whereas the previous study of 
Wang et al. utilized a labor- and time- intensive 384-well format for real-time PCR that required 
highly skilled technicians, we are conducting this revalidation study using proprietary TaqMan 
Array Cards, which are customized to include primers for our specific panel of classifier genes. 
These TACs require minimum technical expertise, ensure a consistent quantity of primers and 
reagents in each well, and produce consistent PCR results using very little quantities of starting 
cDNA material. We believe these features will enhance the viability of the RNA signature as a 
future diagnostic test, and will determine in this study whether the results and outcomes from 
using this proprietary technology are consistent with those in Wang et al. 
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Methods 
 
Selection and Enrollment of Patients and Controls 
This study was approved by the Yale University Human Investigation Committee 
(Protocol # 0109012617).  
All patients who present to the Aortic Institute at Yale-New Haven Hospital (Director, Dr. 
John A. Elefteriades) for consultation and who have a documented ascending TAA, based on 
definitive radiographic evidence and a physician’s evaluation, are eligible for this study. 
Acceptable radiographic modalities include ECHO, CT, MRI, and angiogram (aortogram). 
No specific selection criteria are made based on gender, age, or ethnic background. 
Patients who have had their TAAs surgically resected are also included, as long as there is at 
least one year’s time between the time of surgery and time of blood specimen collection. 
Patients with TAAs as part of a connective tissue disorder, such as Marfan syndrome, 
were excluded. Patients with active leukemia or other blood dyscrasias that may distort the 
constituents of the peripheral blood sample collected, or patients treated with chemotherapy 
within the past year that may likewise distort the blood sample, were excluded as well. 
Spouses were enrolled as controls because they generally share similar age, diet, 
geography, and ethnicity as the enrolled patients. All patients and controls have given advanced 
written consent for inclusion in this study. A questionnaire was administered to participants to 
collect data on age, height, weight, medications, medical history, and family history. 
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Selection of Target Classifier Genes 
The 41 classifier genes that comprise the RNA signature panel were identified through 
microarray analysis, as described in Wang et al. (49). Briefly, peripheral blood was collected 
from 58 TAA patients and 36 spousal controls using the PAXgene Blood RNA Tubes (Qiagen, 
Valencia, CA). Total RNA was extracted from each sample (PAXgene Blood RNA Kit, PreAnalytiX, 
Qiagen), and used as template for the synthesis of digoxigenin-UTP labeled cRNA using the 
Chemiluminescent RV-IVT Labeling Kit v 1.0 (Applied Biosystems, Foster City, CA). The 
hybridization was performed using the Human Genome Survey Microarray v 2.0 (Applied 
Biosystems), which contains probes for 29,098 individual human genes. Array hybridization was 
performed for 16 hours at 55oC.  Chemiluminescence detection, image acquisition, and analysis 
were performed using the Chemiluminescence Detection Kit and 1700 Chemiluminescent 
Microarray Analyzer (Applied Biosystems). The significance analysis of microarrays (SAM) 
software (Stanford, Palo Alto, CA) was used to identify potential signature genes.  
The microarray analysis to identify potential signature genes, as described above, was 
not performed or repeated in this current study. 
RNA Collection and Extraction (PAXgene) 
2.5 mL of whole blood was collected in PAXgene Blood RNA Tubes (Qiagen) from 
enrolled patients and spouses using standard phlebotomy techniques (using the BD Vacutainer 
Safety-Lok Blood Collection Set (Becton, Dickinson and Company, Franklin Lakes NJ)). PAXgene 
Blood RNA Tubes contain a proprietary reagent that protects RNA from degradation by RNases, 
and minimizes in-vitro (post-phlebotomy) alterations in gene expression. Blood samples were 
allowed to incubate at room temperate (25oC) for 2 to 3 hours for lysis of blood cells, and then 
stored at 4oC overnight for 24 hours. Blood tubes were then stored at – 80oC for long-term 
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storage. Prior to RNA extraction, the blood specimen was thawed at 4oC for 24 hours, and then 
equilibrated to room temperature for 2 to 3 hours (per kit protocol). 
RNA extraction was performed using the PAXgene Blood RNA Kit (PreAnalytiX, Qiagen). 
PAXgene Blood RNA Tubes containing patient samples were centrifuged at 3000 g for 10 
minutes. The supernatant was decanted. 4 mL of RNase-free water was added to the pellet, and 
vortexed until the pellet dissolved. The tube was centrifuged again at 3000 g for 10 minutes. The 
supernatant was decanted. 350 μl of Buffer BR1 (provided with kit) was added to pellet, and 
vortexed. The entire sample was then transferred by pipet to a 1.5 mL microcentrifuge tube. 300 
μl of Buffer BR2 and 40 μl of proteinase K were added to the sample. The sample was then 
incubated for 10 minutes at 55oC using a shaker-incubator at 400 rpm. 
The lysed sample was subsequently transferred to a PAXgene Shredder spin column 
placed in a 2 mL processing tube, and centrifuged for 3 minutes at 13400 g. The flow-through 
containing the sample was transferred to a new 1.5 mL microcentrifuge tube. 350 μl of 100% 
ethanol was added to the flow-through, and vortexed. The sample was then transferred into the 
PAXgene RNA spin column placed in a 2 mL processing tube, and centrifuged for 1 minute at 
13400 g (samples were centrifuged in the PAXgene RNA spin column in two allotments, and the 
flow-through was discarded for each). 350 μl of Buffer BR3 was added to the PAXgene RNA spin 
column, and centrifuged for 1 minute at 13400 g. The flow-through was decanted. A mixture of 
10 μl of reconstituted DNase I and 70 μl of Buffer RDD was added to the spin column, and the 
sample was incubated at room temperature for 15 minutes. 
The PAXgene RNA spin column was then washed with 350 μl of Buffer BR3 (centrifuged 
for 1 minute at 13400 g, and the flow-through was decanted). Afterwards, the spin column was 
washed twice with 500 μl of Buffer BR4 (centrifuged for 1 minute and 3 minutes, at 13400 g). 
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After the last flow-through was decanted, the spin column was centrifuged again for 1 minute 
for 13400 g to spin out residual buffer. The spin column containing the extracted RNA was then 
transferred to a new 1.5 mL microcentrifuge tube. 40 μl of Buffer BR5 was added to the column, 
and allowed to sit for 1 minute at room temperate. The spin column was then centrifuged for 1 
minute at 13400 g to elute the RNA. The spin column subsequently was treated again with 40 μl 
of Buffer BR5, and eluted again. The final eluate (80 uL) was incubated for 5 minutes at 65oC in a 
shaker-incubator without shaking. The eluate containing total RNA sample was immediately 
placed on ice prior to subsequent processing. 
RNA Collection and Extraction (Tempus) 
3.0 mL of whole blood was collected in Tempus Blood RNA Tube (Applied Biosystems) 
from enrolled patients and spouses using standard phlebotomy techniques. The Tempus Blood 
RNA Tubes contains an additive that stabilizes the RNA and in-situ transcription profile. After 
blood collection, the tube was shaken vigorously for 10 seconds to disperse the stabilizing 
reagent within the sample, per protocol recommendations. Blood tubes were then allowed to 
incubate at room temperate (25oC) for 2 to 3 hours for lysis of blood cells, and then stored at 
4oC overnight for 24 hours. Blood tubes were then stored at – 80oC for long-term storage. Prior 
to RNA extraction, the blood specimen was thawed at 4oC for 24 hours, and then equilibrated to 
room temperature for 2 to 3 hours. 
RNA extraction was performed using the Tempus Spin RNA Isolation Kit (Applied 
Biosystems). The blood sample in the Tempus Blood RNA Tube was poured into a clean 50 mL 
conical tube (Ambion, Life Technologies, Carlsbad, CA). Approximately 3 mL of 1X Phosphate-
buffered saline (PBS) was added to the solution to bring the total volume to 12 mL. The conical 
tube was then vortexed at maximum speed for 30 seconds, and centrifuged for 30 minutes at 
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4oC and 3000 g. The supernatant was decanted, and the conical tube (with the pellet) was left 
inverted for 1 minute. Afterwards, 400 μl of RNA Purification Resuspension Solution was added 
to the pellet, and vortexed. 
A purification filter was inserted into a collection tube. 100 μl of RNA Purification Wash 
Solution 1 was pipetted onto the membrane of the purification filter for pre-wetting the 
membrane. The resuspended RNA was then transferred onto the purification filter, and 
centrifuged for 30 seconds at 13400 g (flow-through was discarded). 500 μl of RNA Purification 
Wash Solution 1 was added to the purification filter, and centrifuged for 30 seconds at 13400 g 
(flow-through was discarded). 500 μl of RNA Purification Was Solution 2 was added to the 
purification filter, and centrifuged for 1 minute at 13400 g (flow-through was discarded). A 
mixture of 10 μl of reconstituted DNase I and 70 μl of Buffer RDD was added to the purification 
filter, and the sample was incubated at room temperature for 15 minutes. 
After DNase I treatment, 500 μl of RNA Purification Wash Solution 2 was added to the 
purification filter, incubated at room temperature for 5 minutes, and then centrifuged for 30 
seconds at 13400 g (flow-through was discarded). Another 500 μl of RNA Purification Wash 
Solution 2 was added to the purification filter for a second wash (centrifuged for 30 seconds at 
13400 g; flow-through was discarded). The purification filter was then centrifuged by itself for 
30 seconds at 13400 g to dry the filtration membrane.  The purification filter was subsequently 
transferred to a new collection tube. 100 μl of Nucleic Acid Purification Elution Solution was 
added to the purification filter, and incubated for 2 minutes at 70oC. The purification filter was 
then centrifuged for 30 seconds at 13400 g. The eluate containing the RNA was pipetted back 
into the same purification filter, and centrifuged for 2 minutes at 13400 g. The eluate containing 
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total RNA sample was then transferred to a clean 1.5 mL microcentrifuge tube, and placed on 
ice prior to subsequent processing. 
RNA Quantification/Quality Assessment 
5 μl of total RNA for each sample was sent to the Yale Center for Genome Analysis 
(formerly Keck Microarray Core Facility) for RNA quantification and quality assessment (300 
Heffernan Drive, B36 West Haven, CT 06516). RNA quantification was performed using the 
NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA). RNA integrity was 
determined by electrophoresis using the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA).  
RNA quantification and quality assessment were performed at a Core Facility, and not by 
the authors of this current study. 
cDNA Synthesis 
Total RNA was reverse-transcribed into cDNA for real-time PCR analysis using the 
QuantiTect Reverse Transcription Kit (Qiagen). 2 μl of 7X gDNA Wipeout Buffer was added to 
200 ng of each RNA sample, and the total volume was brought to 14 μl with RNase free water. 
The mixture was incubated for 2 minutes at 42oC, and immediately placed on ice. 
After incubation, the following was added to each sample: 1 μl Quantiscript Reverse 
Transcriptase, 4 μl Quantiscript RT Buffer (5X), and 1 μl RT Primer Mix, bringing the total 
reaction volume to 20 uL. The reaction mixture was incubated for 30 minutes at 42oC. The 
reaction mixture containing cDNA was then deactivated at 95oC for 2 minutes, and stored on ice. 
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Preparing the TaqMan Array Cards 
The TaqMan Array Cards (Production Number: 1198801 and 1198802; Sales Order: 
186436998 and 186437213) were generously provided by Applied Biosystems. Each TaqMan 
Array Card (TAC) is an 8-lane system; each lane (fill reservoir) branches off to 48 different wells. 
Each well contains the TaqMan Gene Expression Assay, a pre-loaded and desiccated mixture of 
sequence-specific primers (TaqMan MGB Probes) customized for our panel of classifier genes 
(Fig 1). The exact sequences of the primers are proprietary and not currently available. 
20 μl of template cDNA was mixed with 80 μl of RNase/DNase-free water and 100 μl of 
TaqMan Gene Expression Master Mix (2X) (Applied Biosystems), producing a total volume of 200 
μl per sample. The TaqMan Gene Expression Master Mix contains AmpliTaq Gold DNA 
Polymerase, Uracil-DNA Glycosylase, deoxyribonucleotide triphosphates, ROX Passive Reference, 
and buffer solution. The sample was gently vortexed. 
The TACs, stored at 4oC, were allowed to reach room temperate. 100 μl of each sample, 
containing cDNA synthesized from approximately 100 ng of total RNA (for each sample), was 
loaded into each lane on the TAC. Two replicates (two lanes) were run per sample, for a total of 
four samples per TAC. Proper attention was given to loading each lane port without air bubbles, 
and without damaging the foil at the base of the port. 
Once all eight lanes were loaded with cDNA/Master Mix (100 μl per lane), the TAC was 
loaded onto array holders and Sorvall Custom Buckets for centrifugation using the Sorvall 
Legend XT (Thermo Scientific). Generous permission was received from the laboratory of Dr. 
Jeffrey L.  Sklar, Department of Pathology, Yale University School of Medicine, for the use of the 
centrifuge. The centrifugation process allows the samples to be distributed from the fill 
reservoir to each of the 48 reaction wells branching off of each lane. The TACs were centrifuged 
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on a custom setting (#15679) for two consecutive 1 minute segments at 331 g. After 
centrifugation, the fill reservoir of TAC was examined manually to ensure uniform and 
consistent distribution of sample. 
The TACs were then individually sealed using a sliding carriage contraption to seal the 
sample fluidics within each well. Proper care was taken for correct orientation, placement, and 
removal of the TAC prior to and after sealing. The fill reservoirs were then trimmed off the TACs 
using generic scissors. 
Real-Time Polymerase Chain Reaction 
Real-time PCR was performed using the 7900HT Fast Real-Time PCR System 
thermocycler (Applied Biosystems). Generous permission was received from the laboratory of Dr. 
Clifford W. Bogue, Department of Pediatrics, Yale University School of Medicine, for the use of 
the thermocycler. Prior to use, a custom block and precision plate holder was installed on the 
7900HT thermocycler to ensure proper physical fit, cycling conditions and fluorescence 
detection of the TACs. 
SDS v2.3 software (Applied Biosystems) was used to operate the real-time PCR cycling 
procedure. The real-time PCR settings were selected as follows:  
• Assay Type: ∆∆Ct (RQ) 
• Container: 384 Wells TaqMan Low Density Array 
• Template: Blank Template 
An .SDS setup file was provided by Applied Biosystems accompanying our specific TAC 
and gene layout. This setup file was imported into the SDS software prior to the start of real-
time PCR to configure the well-specific array data (including the gene name of each well 
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location). The sample name and ID of each loading port was entered manually. The remainder of 
the settings used was default. 
The default thermal cycling conditions were used:  
• 50.0oC for 2 minutes   
• 94.5oC for 10 minutes   
• Forty (40) cycles of (97.0oC for 30 seconds, then 59.7oC for 1 minute).  
RQ Manager v1.2 software (Applied Biosystems) was used to analyze the raw data of 
real-time PCR. The .SDS files containing data for the real-time PCR runs for each TAC were sent 
electronically to molecular biostatisticians at Life Technologies.  
The ∆∆Ct (RQ) analysis for all samples to quantify the relative expression of each of the 
classifier genes was performed by biostatisticians at Life Technologies. 
Classification Model and Statistical Analysis 
The model for classifying each sample as “TAA Patient” or “Spousal Control” was based 
on previously applied methods (49). The relative expression levels of the classifier genes were 
used to classify each sample as either a patient or a control using the comparative ΔCt method 
(ΔΔCt) and a 10- fold cross-validation test.   
For each gene in the panel, the output from the TaqMan real-time PCR analysis is a 
relative expression level of that gene versus the expression level of an endogenous control (PPIA 
gene), expressed as ΔCt. The ΔCt was averaged across replicates to remove sample input errors 
and natural biological variation. 
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The ΔCT values that constitute the expression profile of each individual gene in sample X 
= (x1,…,x41) was inserted into the defined linear classifier regression. This classifier is based on 
the two discriminant scores: 
 
where  is the average expression level of gene i in class k of previously used samples, 
si is the pooled within-class standard deviation for gene i, s0 is the median value of the si  over all 
genes, and πk is prior probability of class k (the overall frequency of class k in the population), 
where π1 + π2 = 1.  
The regression predicts that sample X* is a case (k = 1) if δ1(x*) < δ2(x*) and control 
otherwise.  
Discriminant scores were used to estimate class probabilities, by analog to Gaussian 
linear discriminant analysis: 
 
 
Based on these two scores and a 10-fold cross-validation study, using reiterative bins of 
four random samples (3 TAA samples and 1 control, 2 TAA samples and 2 controls, etc), each 
sample was given a probability of being a TAA (case) sample. This probability was used to 
classify each sample as either “case” (TAA patient) or “control” (no aneurysm); a sample was 
classified as a case if its probability of being a case exceeded 50% (and vice versa). The predicted 
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defined by their clinical diagnosis, to compute an absolute number of true positives (TP), true 
negatives (TN), false positives (FP), and false negatives (FN). The sensitivity (TP/(TP+FN)), 
specificity (TN/(FP+TN)), and accuracy ((TP+TN)/total) were then calculated. 
The ∆∆Ct (RQ) analysis for all samples and the multiple regression algorithms used to 
predict the clinical status of each sample (“aneurysm” or “no aneurysm”) was performed by 
biostatisticians at Life Technologies. 
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Results 
 
Patient Demographics 
Twenty-four patients with confirmed TAAs and sixteen spouses were enrolled in this 
validation study. Table 1 summarizes their clinical features. Of note, two spousal controls were 
lost to follow-up, before their clinical information could be obtained. 
Most of the TAA patients (79%) were men, whereas only 19% of the spousal controls 
were men. Patients and controls share similar age (59 years) at time of blood collection, but TAA 
patients were slightly taller, likely secondary to the gender disparity. The patient and control 
groups had similar rates of hypertension (63% versus 64%), cigarette smoking (25% versus 29%), 
and diabetes (8.3% versus 7.1%). TAA patients had a higher prevalence of cardiac comorbidities 
than spousal controls (50% versus 7.1%); these comorbidities include coronary artery disease, 
arrhythmias, and heart failure. 
All 24 TAA patients had their aneurysms in the ascending portion of the aorta. Five of 
these patients had aneurysms that additionally extended to the aortic arch. The average size of 
the TAAs was 5.18 cm, ranging from 4.5 cm to 6.9 cm. Seven of the 24 samples were obtained 
from TAA patients post-operatively. A high percentage (54%) of TAA patients also had bicuspid 
aortic valves. 58% of TAA patients had a family history positive for aortic aneurysms or 
presumed “cardiac” sudden death, as compared to only 7.1% of spousal controls. 
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Comparison of RNA Extraction Methods 
The first 17 blood samples were collected using PAXgene Blood RNA Tubes (Qiagen), 
based on the previous study by Wang et al (49). However, for economic reasons, subsequent 
samples were collected using the Tempus Blood RNA Tubes (Applied Biosystems). 
A comparison was made between the quantity (concentration) as well as the quality of 
the RNA isolated with each system (Appendix 1). The average RNA concentration of samples 
isolated with the PAXgene system was 95.7 ng/μL, versus 135.94 ng/μL for RNA samples isolated 
with the Tempus system (p < 0.01, two-tailed T-test). 
The 260/280 absorption ratio, a traditional measure of the protein contamination of 
nucleic acid samples, was assessed between the PAXgene samples and the Tempus samples. 
While the 260/280 ratios for samples isolated with either method were greater than 2, 
signifying a “pure” sample, the PAXgene samples had an average 260/280 ratio of 2.14, 
compared with 2.07 for the Tempus samples (p < 0.01). 
Additional RNA quality control was performed using the 2100 Bioanalyzer, which uses 
microfluidic electrophoresis to determine RNA quality (Appendix 2). The Bioanalyzer system 
generates a RIN, or “RNA Integrity Number,” ranging from 0 to 10, to reflect the purity and 
quality of RNA samples. Samples with higher RINs are considered to be of higher quality. The 
PAXgene samples had an average RIN of 7.53, whereas the Tempus samples had an average RIN 
of 6.36 (p < 0.05). 
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TaqMan Real-Time PCR Assay Validation 
Customized TaqMan Array Cards incorporating the panel of classifier genes (the RNA 
signature) identified in Wang et al. were generously provided by Life Technologies. An 
accompanying array map (Fig 1) displays the identity of the genes in each well. In the 48-well 
array used in this study, four wells are empty, one well contains the endogenous control gene 
(PPIA), and 43 wells contain classifier genes. After cross-matching the list of genes with those 
found in the original study, only 39 of the 41 genes identified in Wang et al. were found to be 
incorporated in this current TaqMan Array Card (see Table 2 for a list of the 39 genes). 
During real-time PCR, six of these 39 genes showed poor amplification after standard 
cycling conditions, across all 40 blood RNA samples (24 patients, 16 controls). For the 33 genes 
that amplified successfully, the average number of cycles needed to amplify the target past the 
preset fluorescence detection threshold (the Ct value) across samples ranged from 16 to 29 (Fig 
2A). By contrast, for the six genes that failed to amplify, no appreciable or consistent 
fluorescence was detected by cycle 40 (Fig 2B). Therefore, the final prediction algorithm is based 
on the relative expression levels of 33 genes. The coefficients of the six genes that failed to 
amplify are 0, and therefore do not contribute to the prediction model.  
After a 10-fold cross-validation test of the 24 TAA samples and 16 control samples, using 
the delta-delta-Ct values of each gene for each sample and the previously developed prediction 
algorithm (49), a cross-validation probability (0-100%) was calculated for each sample; this 
probability reflects the likelihood that the particular sample is from a TAA patient (Fig 3). Based 
on this cross-validation, 25 samples were classified as “TAA” and 15 samples were classified as 
“controls”. 
33 
 
 
When each sample’s predicted diagnosis was compared with the sample’s true clinical 
diagnosis (the actual status of the individual donating the blood sample), the RNA signature test 
was 83% accurate: 
 True Clinical Status  
TAA Control 
Predicted Status 
(Cross-Validation) 
TAA 21 4 25 
Control 3 12 15 
 24 16 40 
 
The sensitivity of the test was 88%, and the specificity of the test was 75%. Table 3 
compares the characteristics and testing parameters of the current validation study with that of 
the previously published study. 
 
Comparison of Gene Expression Patterns with Previous Study 
The current RNA signature assay is based on the relative expression levels of 33 
different genes in the PBCs of TAA patients versus spousal controls. To test for the consistency 
and reproducibility of the assay, we compared the expression patterns of these 33 genes 
between the current and previous studies. 
To assess whether the expression profiles of the TAA patient samples and spousal 
control samples in our current assay reflect or mirror those of the previously published assay, 
we first compared the average Ct values for each of the 33 classifier genes acquired between 
the previous test and the current test. This analysis was further broken down into two separate 
comparisons, one for TAA patient samples, and one for control samples (Fig 4). 
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For TAA patient samples, the previous real-time PCR study was able to amplify all 
classifier genes, on average, before the 35th cycle (Fig 4A). The average Ct values from the 
previous study ranged from 16 to 35 (x-axis). When plotted against the average Ct values of the 
same genes as determined by the current real-time PCR study, most of the points lie above the 
y=x, signifying that for most of the classifier genes, it took more cycles (higher Ct values) to 
amplify the gene (past the threshold of detection) in our current study than in the previous 
study.  Furthermore, six genes failed to amplify, as mentioned above. However, there was good 
correlation between Ct values from the previous study and Ct values from the current study (r2 = 
0.75), suggesting that the individual genes behave in a somewhat consistent manner between 
the two studies. For example, a gene that was expressed in low amounts in TAA patient samples, 
and thus had a high Ct value (requiring more cycles to amplify) in the previous study, also had a 
high Ct value as determined by the current study. 
For spousal control samples (Fig 4B), the same pattern was observed: the overall 
correlation was good (r2 = 0.73), but most points lied above the y=x line, again signifying that 
these genes required more cycles to amplify in our current study than in the previous study. 
Next, the relative expression levels (the fold-change) of the classifier genes between 
cases and controls were analyzed to determine if they were preserved between the previous 
study and the current study. In other words, if the previous real-time PCR study determined that 
gene X was expressed three times more abundantly in the PBCs of TAA patients relative to 
spousal controls, the fold-change for gene X would equal 3, and we wanted to assess whether 
the fold-change value for gene X in our current study also approximates 3. 
The panel of classifier genes originally identified in Wang et al. included genes that were 
both over-expressed in TAA patients versus spousal controls, as well as under-expressed in TAA 
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patients versus spousal controls (Fig 5A; also see Table 2 in Wang et al., 2007). The fold-change 
values (in log 2) were both positive and negative. By contrast, in the current study, the majority 
of the same panel of genes appears to be over-expressed in TAA patients relative to spousal 
controls (Fig 5B, Fig 6). Quantitatively, the average fold-change (log 2) in expression levels of 
control samples relative to TAA samples (for all genes) in the current study is -0.328, denoting a 
relative under-expression of the panel of 33 classifier genes in control patients (Table 2).  The 
previous study, on the other hand, demonstrated that the average fold-change (log 2) for the 
same 33 genes is +0.034, signifying a very slight trend towards over-expression in control 
patients. The eight genes that either did not amplify in the current assay, or were not included 
in the TaqMan Array Cards, were excluded from this calculation. Altogether, the newly designed 
assays for the same set of genes show a bias for up regulation in TAA samples relative to 
controls. 
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Discussion 
 
The clinical features of thoracic aortic aneurysms render the disease sorely in need of a 
screening test. TAAs are clinically-silent, life-threatening, and treatable with surgery. With timely 
diagnosis, we eliminate the risk of TAAs becoming a “silent killer”, and can offer patients options 
in living with or treating this condition. 
There are currently no screening programs for TAA. In this era of molecular medicine, 
many technologies have become available to help identify biomarkers of disease and promising 
therapeutic targets. Molecular diagnostics have not yet been utilized clinically for TAAs, but 
there is mounting evidence that gene expression profiles might play a role in screening for and 
detecting TAAs. A previously published study from our institution utilized microarray technology 
to identify genes that were over-expressed or under-expressed in circulating leukocytes in a 
consistent, detectable manner in TAA patients versus spousal controls (49). A panel of 41 
classifier genes, identified through this method, was engineered into a “RNA signature” that was 
80% accurate for detecting TAA. Many of these genes are involved in the inflammatory process 
or pathogenesis pathways of TAAs, providing a mechanistic basis for why this signature might be 
able to detect TAAs. 
Our current investigation is a validation study, with the purpose of demonstrating 
whether this RNA signature is reproducibly accurate, and whether this signature has potential to 
become a clinical laboratory test for TAA. We elaborate the findings of the Wang et al. study in 
two ways: 1) our testing samples come from a newly recruited cohort of TAA patients and 
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spouses and are independent from the samples used in the original microarray analysis, and 2) 
our blood RNA samples are tested on a commercialized TAC platform that more closely 
resembles the real world configuration of an actual diagnostic test, instead of a 384-well format 
commonly used in basic research settings. 
Forty individuals were recruited for this current study—24 patients with radiographically 
documented TAAs, and 16 healthy, spousal controls. Analysis of the peripheral white blood cell 
RNA signature for these individuals, using the TaqMan real-time PCR system, generated a 
probability for each individual having TAA disease. When these probabilities were converted to 
categorical classifications of “TAA patient” or “spousal control” for each sample, the signature 
was 83% accurate in discriminating TAA samples from the control samples. The signature was 88% 
sensitive and 75% specific. 
The overall accuracy of the assay is comparable to that of the previous study (83% 
versus 80%). The current TAC format with 33 viable classifier genes has a higher sensitivity (88% 
versus 71%) but lower specificity (75% versus 100%), when compared with the results of the 
previous study (Table 3). 
Several additional comparisons can be made between the current results and the results 
of the previous study. First, as shown in Figure 4, for most genes that were successfully 
amplified, the current TAC platform required a higher number of cycles of amplification before 
the gene product can be detected (as reflected by the higher Ct values), compared with the 384-
well platform. This systematic shift in the Ct values is likely a function of the smaller amount of 
starting cDNA used in the TAC-based real-time PCR amplification. Because the baseline amount 
of cDNA is lower, more cycle numbers are required to amplify the gene targets past the set 
threshold of detection. The fact that a smaller amount of starting cDNA template (and therefore, 
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starting RNA quantity) can produce the same high level of diagnostic accuracy is an advantage of 
the TAC platform, and is an inherent feature of the microfluidics design of the system. The 
microfluidics allow for very small amounts of sample to uniformly populate dozens of wells and 
produce consistent amplification of the targets. No pre-amplification step is needed. In a clinical 
laboratory setting, this test can theoretically be accurate even with a small quantity of blood. 
Second, several gene targets did not amplify during real-time PCR in our current study, 
whereas they did amplify in the previous study. One possibility is that there is a manufacturing 
error with the TACs, such that some wells did not contain proper amounts of reagents. Another 
possibility, based on the findings in Figure 4A, is that the genes that failed to amplify in the 
current study were those that had high Ct values in the previous study, and therefore were 
genes that were expressed in low levels. In our current assay, because we used smaller amounts 
of starting material, the quantity of these targets could have been too low for detection even 
after 40 cycles. 
In addition, two of the original 41 classifier genes did not even appear in our custom-
made commercial TaqMan Array Cards. Again, this can reflect a manufacturing error or an error 
in the ordering process for these Array Cards. 
Regardless, the consequence is that our current assay relies on the coefficients and 
contributions of only 33 genes, instead of the full panel of 41 classifier genes as identified in the 
previous study. However, the overall accuracy of the assay was not negatively affected by 
having eight fewer genes. Interestingly, the sensitivity actually improved, whereas the specificity 
worsened. As a screening test, a high sensitivity is a critical parameter, even at the cost of high 
specificity. The finding that removing eight genes actually improves the sensitivity of the assay 
suggests the need for future studies to examine the receiving operating characteristic (ROC) 
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curve as a function of number of genes (and which genes) are included in the assay. Such ROC 
curves can help determine the optimal number of genes that should appear in the final version 
of the RNA signature assay. 
Third, as shown in Figure 5 and Figure 6, most of the genes in our current assay appear 
to be over-expressed in the PBCs of TAA patients compared to controls. By contrast, 
approximately half of the genes in the previous assay were under-expressed in TAA patients, 
while the other half of the genes were over-expressed. It is unclear what the underlying cause of 
this discrepancy is. One possibility is that several genes in our RNA signature assay are not, as 
we have hypothesized, consistently over- or under-expressed in the peripheral blood cells of 
TAA patients versus controls. Instead, they can be confounder genes that only appear to be 
expressed in consistent manners in the original cohort of samples, but actually are not in fact a 
“signature” of TAA disease. Nonetheless, our current assay can still distinguish TAA patients 
from controls with a high level of accuracy. 
Altogether, we have demonstrated that a modified 33-gene RNA signature assay 
accurately detects TAA from healthy, spousal controls, using a sample of blood alone. This assay 
has strong potential to be the basis of a clinical laboratory test for TAAs. This RNA signature 
assay for TAA is safe, non-invasive, and cost-effective.  Individuals who are tested “positive” by 
this assay will then be subsequently referred for more extensive work-up, including radiographic 
imaging. Individuals at higher risk for harboring or developing a later aneurysm, including older 
individuals and those with a family history of TAAs, can be repeatedly monitored with this assay 
over time, without the risk of accumulating radiation or contrast toxicity. 
The customized, prefabricated TaqMan Array Cards used in this assay allow for 
considerable streamlining of work, eliminating the need to manually preload dozens of 
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individual wells with standardized amounts of gene-specific primers. The single-loading-port 
system also distributes samples evenly to all wells. In addition, the TaqMan system is a highly 
accurate method for quantification of expression levels of genes, because the fluorescent 
reporter is covalently attached to each sequence-specific primer. The report will only fluoresce 
once the nearby quencher molecule, also attached to the primer, is digested away during the 
polymerization step. This reduces the incidence of background, noise, and false-positive 
fluorescence. Lastly, the TaqMan Array Cards can be easily modified in the future to add or 
remove genes, and can be easily mass produced for clinical use across the country. In summary, 
the TaqMan platform allows for high-throughput surveillance of the expression levels of 
multiple genes in a convenient enough manner to allow utilization in most regular diagnostic 
laboratories, instead of requiring a highly sophisticated research laboratory and staff. This is 
ideal for a clinical blood test. 
There were several limitations to this validation study. While using spouses as controls is 
ideal for matching age, ethnicity, diet, and geography, it does not control for gender. Since there 
are possible gender-based differences in the expression levels of one or more of our genes of 
interest, the ideal setup would have similar numbers of male and female patients (and controls). 
However, we have limited our study sample to patients with ascending TAAs, which may be 
more prevalent in men than in women (4). 
Secondly, we made the assumption that all spousal controls are free from TAA disease, 
based on 1) the relatively low population prevalence of the disease, and 2) the self-report of all 
spouses. However, none of the enrolled spouses had radiographic evidence that definitively 
rules out thoracic aneurysms. We felt that imposing such an inclusion criterion for controls 
would result in either low enrollment of spouses, or enrollment of spouses with other 
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comorbidities, since healthy individuals generally do not have ECHOs, CT scans, or MRI scans. In 
addition, requesting that spouses obtain imaging just for the purposes of this study would be 
prohibitively expensive, and medically contraindicated. 
We also enrolled a few TAA patients who have already had their aneurysms replaced. All 
such patients had their surgeries more than one year prior to the time of blood collection, and 
we expect that any blood products they received during their hospitalization had washed out.  
We presume that an underlying “aneurysm” molecular biology persists systemically even after 
aneurysm resection. However, it is possible that either the stress and inflammatory response 
associated with surgery, or the presence of a foreign body, permanently altered the expression 
profiles of these patients’ circulating leukocytes. Since we are developing a screening test, our 
ideal test population would all be pre-operative patients. 
Lastly, we used two different blood collection and RNA stabilization systems, the 
PAXgene and the Tempus Blood RNA tubes. We had initially believed that because we are 
measuring the relative, and not absolute, expression levels of a panel of genes, the quality and 
quantity of RNA extracted from blood would not affect the outcome. However, published 
studies have demonstrated that samples isolated with PAXgene and Tempus systems amplify 
differential subsets of genes, including some interleukins (which are found in our current assay 
of genes) (53). Fortunately, the overall accuracy of our assay in detecting TAA did not appear to 
be negatively affected. Future studies must utilize a single and uniform RNA isolation system. 
Future studies will focus on generalizing these current findings to a cohort that more 
closely resembles the population-to-be-screened. A true prospective validation study in which 
consecutive individuals with unknown TAA statuses are tested with this RNA signature assay, 
and then compared to a gold standard, will be the ultimate proof of the clinical utility of this 
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assay. However, this setup will require a prohibitively high number of participants before 
enough de novo TAAs can be detected with this assay. Thus, such an experiment would be 
unfeasible for TAAs. A more feasible prospective study would involve a small subset of the 
general population in which the prevalence of TAA is already high, such as the family members 
of TAA patients. 
Subgroup analysis is a natural extension of this current study. For example, we can 
interrogate the assay with just male patients against male controls, or examine whether the 
assay performs well for TAA patients with bicuspid valves. An evaluation of whether this assay is 
sensitive for TAAs in patients with connective tissue disorder, whom we have intentionally 
excluded from this current study, is already underway by our group. 
In order to demonstrate the specificity of this assay for TAAs, as opposed to being able 
to detect any cardiovascular, inflammatory, or aneurysmal disease, future studies can evaluate 
whether the assay can distinguish TAA patients from patients with coronary artery disease, 
intracranial aneurysms, and abdominal aortic aneurysms, or, possibly, whether the signature 
can detect these other aneurysm types as well. In our current cohort, significantly more TAA 
patients have other cardiac conditions than spousal controls (Table 1), again raising the question 
of whether our RNA signature is specific for TAAs.  We must rule out the possibility that the RNA 
signature detects cardiac disease in general. 
Finally, the thermocycler used for real-time PCR in this study, the 7900HT Fast Real-Time 
PCR System thermocycler (Applied Biosystems), is being phased out of use in research and 
diagnostic laboratories, and will be replaced with the ViiA7 Real-Time PCR System (Applied 
Biosystems), and possibly even newer models, by the time this assay is ready for clinical use. 
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Such is the rapid pace of molecular genetics in the current era. Therefore, a validation study 
should be repeated using the latest line of real-time thermocyclers.  
We envision that the widespread availability of such thermocyclers, even in a few 
laboratories per state, and the widespread distribution of the TACs customized with our RNA 
signature assay, can make this screening test for TAA available nationwide. We hope that our 
promising findings regarding the accuracy of this RNA signature in detecting TAA, and future 
commercialization of the assay, will produce a powerful tool in preventative cardiology. Such a 
tool will lead to earlier diagnosis of silent thoracic aneurysms and earlier access to treatment, 
thereby reducing the mortality of this disease. 
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Figures 
 
 
Case Control 
Sample Size 24 16 
Percent Male 79% 19% 
Mean Age (Range) 59 (26-81) 59 (46-80) 
Mean Height in Inches (Range) 69 (58-75) 66 (62-71) 
Mean Weight in Pounds (Range) 182 (90-247) 185 (120-295) 
   
Aneurysm Type: Ascending Alone 19/24 - 
Aneurysm Type: Ascending and Arch 5/24 - 
Average Size in cm (Range) 5.18 (4.5 - 6.9) - 
Post-operative Sample 7/24 (29%) - 
Bicuspid Aortic Valve 13/24 (54%) - 
Family History of Aortic Aneurysms 14/24 (58%) 1/14 (7.1%) 
   
Hypertension 15/24 (63%) 9/14 (64%) 
Smoker 6/24 (25%) 4/14 (29%) 
Hyperlipidemia 15/24 (63%) 6/14 (43%) 
Diabetes 2/24 (8.3%) 1/14 (7.1%) 
Non-Valvular Heart Disease 12/24 (50%) 1/14 (7.1%) 
 
 
Table 1. Summary of clinical characteristics of enrolled patients (case) and spouses (control). 
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GeneSymbol AssayID Median Ct 
(TAA) 
Median Ct 
(Control) 
FC(Control/TAA) FC(Control/TAA) 
from Wang et al. 
AKR1B1 Hs01091556_g1 20.342 20.872 -0.530 0.527 
APOA1BP Hs00603256_m1 20.653 20.910 -0.257 0.000 
ATAD3A Hs01587333_m1 23.593 24.553 -0.960 0.077 
ATP5G1 Hs00829069_s1 19.754 19.742 0.012 0.707 
C10orf99 Hs01379644_m1 35.000 35.000 0 -1.292 
C14orf138 Hs00757319_s1 22.495 22.527 -0.031 -0.216 
C15orf63 Hs00742666_s1 24.186 25.038 -0.853 -0.283 
CDK4 Hs00364847_m1 20.865 20.760 0.105 0.043 
CUTA Hs00360405_g1 18.856 18.807 0.049 0.200 
EDF1 Hs00610154_g1 18.144 17.957 0.187 0.355 
ENPP4 Hs00208830_m1 24.787 25.645 -0.858 -0.190 
HMOX2 Hs01558389_m1 20.831 21.440 -0.609 0.389 
IL18R1 Hs00977687_m1 25.215 26.575 -1.360 -0.625 
IMPDH2 Hs01021357_g1 23.726 23.814 -0.088 0.369 
MED6 Hs00902624_m1 21.840 21.841 -0.001 -0.199 
MIF Hs00236988_g1 17.166 16.873 0.293 0.200 
hCG19900 Hs00202945_m1 28.582 27.598 0.984 -0.071 
hCG1773879 Hs01000283_s1 25.521 26.506 -0.985 0.157 
hCG2042278 Hs01039755_s1 24.561 25.488 -0.927 -0.063 
hCG2036771 Hs01568938_m1 35.000 35.000 0 -0.653 
NOSIP Hs01119990_g1 18.815 18.917 -0.102 0.694 
NR1I2 Hs01114267_m1 35.000 35.000 0 0.155 
NUDC Hs00702452_s1 19.810 19.714 0.096 0.548 
NUDT5 Hs00274029_m1 21.413 21.662 -0.248 -0.011 
PCDHA12 Hs00259025_s1 35.000 35.000 0 -0.718 
PHB Hs00855044_g1 22.289 22.471 -0.182 -0.100 
PPAN Hs00220301_m1 22.139 22.177 -0.038 -0.236 
RGS3 Hs00367777_m1 20.497 21.219 -0.722 -0.153 
RUVBL1 Hs01031910_m1 23.359 23.913 -0.553 0.466 
SBSN Hs00415561_m1 35.000 35.000 0 -0.280 
SERF2 Hs00428481_m1 18.246 17.991 0.255 -0.927 
SLC25A24 Hs00534808_s1 23.216 23.137 0.079 -0.772 
SNRPC Hs00853882_g1 19.132 18.719 0.413 0.914 
SOS2 Hs01127279_m1 21.544 21.637 -0.094 -0.915 
SSU72 Hs00204394_m1 18.506 18.514 -0.008 -0.090 
SYNGAP1 Hs01006404_m1 26.886 29.710 -2.824 0.455 
THOC6 Hs00738018_g1 35.000 35.000 0 0.571 
VKORC1 Hs00829655_s1 21.999 22.520 -0.520 -0.163 
VPS72 Hs00195618_m1 23.033 23.571 -0.538 0.049 
 
Table 2. Fold-change in expression level of control samples over TAA samples for each gene. Genes that had fold-
changes equal to 0 correspond to those that did not amplify (no fluorescence detected by the 35th cycle).  
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Table 3. Comparison of the testing characteristics of the three validation studies. 
(TAC: TaqMan Array Card) 
 
  
 
Wang et al. Wang et al. Current Study 
Method Microarray qPCR 
(384-well plate) 
qPCR 
(TACs) 
No. of Genes 41 41 33 
    TAA Samples (N) 22 21 24 
Control Samples (N) 11 9 16 
    Accuracy (%) 78 80 83 
Sensitivity (%) 72 71 88 
Specificity (%) 90 100 75 
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Figure 1. TaqMan Array map of the RNA signature. In this example of a 48-well TaqMan Array 
Card format, each card has loading lanes for eight (8) samples. Each lane will distribute the 
sample to two adjacent rows, each containing 24 wells. Each colored box represents a different 
gene in this customized TaqMan Array Card. “N/A” represents empty wells. PPIA was used as 
the endogenous control. Real-time PCR using the 7900HT Fast Real-Time PCR System utilizes 
such a map file to assign a gene identity to the fluorescence amplification curves emerging from 
each well. 
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Figure 2. Real-time PCR amplification curves. (A). Amplification curve of a single gene across 
eight samples. Each sample is represented by a different colored curve. The fluorescence of 
each sample (y-axis) is shown as a function of cycle number (x-axis). Note the efficient 
logarithmic phase of the amplification starting at cycle 18, followed by a plateau phase. (B). Six 
individual genes, however, failed to amplify by the end of the 40-cycle run. This amplification 
curve shows the failed amplification of one of these genes. Note the lack of a logarithmic phase 
for all eight samples in this representative assay.   
A. 
B. 
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Figure 3. 10-fold cross-validation of the 33-gene RNA signature in predicting aneurysm status. 
After a 10-fold cross-validation study, the probability of each of the 40 samples (vertical column) 
originating from a “TAA patient” was calculated (red dots). This probability ranged from 0 to 
100%, depending on the prediction from the cross-validation. The samples are grouped 
according to their true clinical status (16 Controls, and 24 Patients). The RNA signature is 
successful in predicting the correct clinical status for most samples. 
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Figure 4. Comparison of Ct values between current and previous assay studies. Each gene in 
the assay is represented by a point in the scatterplot. Red points represent the genes that failed 
to amplify in the current assay. (A). For each gene, the Ct values are averaged across all TAA 
patients in the prior assay (“Old Ct”) and across all TAA patients in the current assay (“New Ct”). 
Each gene is then plotted in the appropriate coordinate, at the intersection of the “Old Ct” value 
and “New Ct” value. The y=x line shows an ideal relationship in which the average Ct value for a 
gene is identical between the current and prior assays. The red line represents the loess 
approximation of the measurements. The coefficient of determination (r2) value, listed above 
the scatterplot, describes the linear correlation of the Ct values between the current and prior 
assays. The genes that failed to amplify in the current assay (red dots) did not have fluorescence 
levels that exceeded the threshold even by cycle 35. (B). Similar scatterplot showing the 
correlation between “Old Ct” and “New Ct” values for each gene across all spousal controls. 
  
A. B. 
51 
 
 
 
 
Figure 5: Analysis of the fold-change in gene expression between TAA patients and spousal 
controls. Each gene in the assay is represented by a point in the graph. For each gene, the 
relative expression level of that gene in TAA (case) samples versus spousal (control) samples is 
expressed as a fold-change. Genes near the red (y = 0) line are those that are not expressed in 
significantly different amounts between cases and controls. Genes located above the red line 
are those that are over-expressed in controls relative to TAA patients. Likewise, genes located 
below the red line are those that are under-expressed in controls relative to TAA patients. Red 
points represent genes that failed to amplify in the current study (“New assays”). The y-axis is in 
log 2. (A). In the prior assays (“Old assays”), there are genes that are both over-expressed and 
under-expressed in TAA patients. (B). By contrast, the current assays (“New assays”) shows that 
most genes are over-expressed in TAA patients relative to spousal controls. 
  
  
A. B. 
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Figure 6: Nearest shrunken centroid profiles across the 33 classifier genes. The relative 
expression levels of each of the 33 classifier genes between TAA patient samples and control 
samples are shown as a centroid profile. Left-ward bars represent over-expression, and right-
ward bars represent under-expression. The genes are arranged in descending order of 
magnitude in fold-change expression levels between TAA samples and control samples. As 
shown in this centroid profile, the most discriminatory classifier genes appear to be over-
expressed in TAA patients relative to control samples. 
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96.92 154.82 
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100.64 87.45 
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2.13 2.04 
 
7.7 6.6 
 
62.2 115.32 
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8.5 6.6 
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2.11 2.13 
 
8 6.8 
 
76.9 142.18 
 
2.13 2.11 
 
6.8 7 
 
154.1 109.35 
 
2.10 2.12 
 
7.7 6.7 
 
49.4 166.98 
 
2.23 2.08 
 
8.3 7 
 
97.9 131.01 
 
2.16 2.12 
 
8.1 2.5 
 
159.59 164.70 
 
2.09 2.06 
 
6.8 3 
 
46.63 70.58 
 
2.23 2.13 
 
3.7 8.8 
 
123.1 132.00 
 
2.10 2.09 
 
7.4 8.1 
 
67.5 142.7 
 
2.11 2.05 
 
8 7.2 
 
113.5 118.6 
 
2.08 2.05 
 
8.9 8.4 
 
100.2 138.4 
 
2.11 2.05 
 
8.7 8 
 
48.65 84.7 
 
2.21 2.04 
  
5.3 
 
80.44 124.5 
 
2.15 2.02 
  
7 
  
164.5 
  
2.04 
  
8.1 
  
78.6 
  
2.04 
  
4.1 
  
105.5 
  
2.04 
  
7.8 
  
166.7 
  
2.05 
  
8.6 
  
313.8 
  
2.06 
  
7.5 
         Count 17 22 
 
17 22 
 
15 22 
Mean 95.67 135.94 
 
2.14 2.07 
 
7.53 6.36 
p-value (T-test) 0.0065505 
  
0.0000613 
  
0.0425528 
  
Appendix A. Comparison of PAXgene and Tempus RNA isolation methods. The quantitative 
yield, 260/280 purity ratio, and the RNA Integrity Number (RIN) are listed for each sample 
isolated with either method. All three measures of the performance of an RNA isolation kit are 
statistically significantly different between the PAXgene and Tempus systems. 
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Appendix B. A representative output from the 2100 Bioanalyzer. (A). The integrity and quality 
of each RNA sample is evaluated through electrophoresis. Samples are run against a RNA ladder.  
“High quality” samples show a two characteristic bands, around 4000 and 1800 nt, with very 
little contamination or smear outside of these bands. In this set of samples, lanes 5 and 6 are 
degraded samples (no bands at 4000 and 1800 nt), lane 4 contains low amounts of RNA (low-
intensity bands), and lane 7 contains contamination (extraneous bands). (B). The peak 
fluorescence as a function of molecular size, for the same eight samples. Note the characteristic 
twin peaks, representing the 18S and 28S subunits of RNA. 
  
A. 
B. 
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